title: Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline.
abstract: OBJECTIVE
  A panel was convened by the Health and Science Policy Committee of the American College of Chest Physicians to develop a clinical practice guideline on the medical and surgical treatment of parapneumonic effusions (PPE) using evidence-based methods.
  Based on consensus of clinical opinion, the expert panel developed an annotated table for evaluating the risk for poor outcome in patients with PPE. Estimates of the risk for poor outcome were based on the clinical judgment that, without adequate drainage of the pleural space, the patient with PPE would be likely to have any or all of the following: prolonged hospitalization, prolonged evidence of systemic toxicity, increased morbidity from any drainage procedure, increased risk for residual ventilatory impairment, increased risk for local spread of the inflammatory reaction, and increased mortality. Three variables, pleural space anatomy, pleural fluid bacteriology, and pleural fluid chemistry, were used in this annotated table to categorize patients into four separate risk levels for poor outcome: categories 1 (very low risk), 2 (low risk), 3 (moderate risk), and 4 (high risk). The panel's consensus opinion supported drainage for patients with moderate (category 3) or high (category 4) risk for a poor outcome, but not for patients with very low (category 1) or low (category 2) risk for a poor outcome. The medical literature was reviewed to evaluate the effectiveness of medical and surgical management approaches for patients with PPE at moderate or high risk for poor outcome. The panel grouped PPE management approaches into six categories: no drainage performed, therapeutic thoracentesis, tube thoracostomy, fibrinolytics, video-assisted thoracoscopic surgery (VATS), and surgery (including thoracotoiny with or without decortication and rib resection). The fibrinolytic approach required tube thoracostomy for administration of drug, and VATS included post-procedure tube thoracostomy. Surgery may have included concomitant lung resection and always included postoperative tube thoracostomy. All management approaches included appropriate treatment of the underlying pneumonia, including systemic antibiotics. Criteria for including articles in the panel review were adequate data provided for >/=20 adult patients with PPE to allow evaluation of at least one relevant outcome (death or need for a second intervention to manage the PPE); reasonable assurance provided that drainage was clinically appropriate (patients receiving drainage were either category 3 or category 4) and drainage procedure was adequately described; and original data were presented. The strength of panel recommendations on management of PPE was based on the following approach: level A, randomized, controlled trials with consistent results or individual randomized, controlled trial with narrow confidence interval (CI); level B, controlled cohort and case control series; level C, historically controlled series and case series; and level D, expert opinion without explicit critical appraisal or based on physiology, bench research, or "first principles."
  
  
  METHODS
  The literature review revealed 24 articles eligible for full review by the panel, 19 of which dealt with the primary management approach to PPE and 5 with a rescue approach after a previous approach had failed. Of the 19 involving the primary management approach to PPE, there were 3 randomized, controlled trials, 2 historically controlled series, and 14 case series. The number of patients included in the randomized controlled trials was small; methodologic weaknesses were found in the 19 articles describing the results of primary management approaches to PPE. The proportion and 95% CI of patients suffering each of the two relevant outcomes (death and need for a second intervention to manage the PPE) were calculated for the pooled data for each management approach from the 19 articles on the primary management approach. (ABST
authors.affiliation: Pulmonary and Respiratory Services, Washington Hospital Center, Washington, DC, USA.
authors.forename: G L
authors.initials: GL
authors.lastname: Colice
authors.forename: A
authors.initials: A
authors.lastname: Curtis
authors.forename: J
authors.initials: J
authors.lastname: Deslauriers
authors.forename: J
authors.initials: J
authors.lastname: Heffner
authors.forename: R
authors.initials: R
authors.lastname: Light
authors.forename: B
authors.initials: B
authors.lastname: Littenberg
authors.forename: S
authors.initials: S
authors.lastname: Sahn
authors.forename: R A
authors.initials: RA
authors.lastname: Weinstein
authors.forename: R D
authors.initials: RD
authors.lastname: Yusen
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D019317:Evidence-Based Medicine / Q000379:methods / Q000592:standards; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D010996:Pleural Effusion / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013396:Suction / Q000592:standards; D020775:Thoracic Surgery, Video-Assisted / Q000592:standards; D013907:Thoracostomy / Q000592:standards
chemical_list: D000900:Anti-Bacterial Agents; D005343:Fibrinolytic Agents